Divi's Laboratories Limited (IN:DIVISLAB)
:DIVISLAB
Want to see IN:DIVISLAB full AI Analyst Report?
DIVISLAB Stock Chart & Stats
₹6603.05
-₹20.75(-0.35%)
At close: 4:00 PM EST
₹6603.05
-₹20.75(-0.35%)
Day’s Range― - ―
52-Week Range₹5,637.50 - ₹7,077.70
Previous CloseN/A
Volume63.15K
Average Volume (3M)6.36K
Market Cap
₹1.76T
Enterprise Value₹1.74T
Total Cash (Recent Filing)₹32.61B
Total Debt (Recent Filing)₹900.00M
Price to Earnings (P/E)68.6
Beta0.75
Next Earnings
Aug 03, 2026EPS Estimate
24.03Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)93.63
Shares Outstanding265,468,570
10 Day Avg. Volume6,055
30 Day Avg. Volume6,356
Financial Highlights & Ratios
PEG Ratio3.57
Price to Book (P/B)9.42
Price to Sales (P/S)14.95
P/FCF Ratio317.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹7,717.50Price Target Upside16.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)115.85
Revenue Forecast (FY)₹122.56B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and rising equity provide durable financial flexibility to fund capex, absorb cyclical downturns, and pursue acquisitions or R&D without reliance on external debt. This structural strength supports long-term resilience and strategic optionality across pharma cycles.
Strong Operating Cash GenerationMaterial and rising operating cash flow indicates the core business consistently converts sales into cash, enabling reinvestment in capacity, funding of custom projects, and support for working capital. Sustained cash generation underpins durable internal funding ability.
Scalable API/CDMO Model & Chemistry ExpertiseA dual model—high-volume generic APIs plus custom synthesis/CDMO—creates diversified, repeatable revenue streams. Deep process chemistry and large-scale manufacturing are high technical barriers that support long-term customer relationships and defensible margins in regulated markets.
Bears Say
Uneven Free Cash Flow ConversionVolatile free cash flow and inconsistent conversion of earnings to free cash reduce predictability for dividends, buybacks or debt reduction. Structural capex needs, working-capital swings or project timing can constrain durable shareholder returns and complicate long-term planning.
Margin Normalization And VolatilityA meaningful rollback from 2022 peak margins suggests persistent pricing pressure, product-mix shifts, or higher reinvestment. This structural margin compression can lower return on capital and reduce the sustainability of historically exceptional profitability over multiple years.
Revenue Tied To Product Mix & Customer LifecyclesDependence on product mix and project timing creates structural revenue cyclicality: launches, patent cliffs, or changes in customer sourcing can materially shift demand. This makes long-term top-line predictability and margin stability more challenging for the business model.
Divi's Laboratories Limited News
DIVISLAB FAQ
What was Divi's Laboratories Limited’s price range in the past 12 months?
Divi's Laboratories Limited lowest stock price was ₹5637.50 and its highest was ₹7077.70 in the past 12 months.
What is Divi's Laboratories Limited’s market cap?
Divi's Laboratories Limited’s market cap is ₹1.76T.
When is Divi's Laboratories Limited’s upcoming earnings report date?
Divi's Laboratories Limited’s upcoming earnings report date is Aug 03, 2026 which is in 52 days.
How were Divi's Laboratories Limited’s earnings last quarter?
Divi's Laboratories Limited released its earnings results on May 23, 2026. The company reported ₹28.31 earnings per share for the quarter, beating the consensus estimate of ₹26.433 by ₹1.877.
Is Divi's Laboratories Limited overvalued?
According to Wall Street analysts Divi's Laboratories Limited’s price is currently Undervalued.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.46%. See more information on Divi's Laboratories Limited dividends here
What is Divi's Laboratories Limited’s EPS estimate?
Divi's Laboratories Limited’s EPS estimate is 24.03.
How many shares outstanding does Divi's Laboratories Limited have?
Divi's Laboratories Limited has 265,468,570 shares outstanding.
What happened to Divi's Laboratories Limited’s price movement after its last earnings report?
Divi's Laboratories Limited reported an EPS of ₹28.31 in its last earnings report, beating expectations of ₹26.433. Following the earnings report the stock price went up 4.889%.
Which hedge fund is a major shareholder of Divi's Laboratories Limited?
Currently, no hedge funds are holding shares in IN:DIVISLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Divi's Laboratories Limited
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and animal feed industries. The firm was formerly known as Divi's Research Center before rebranding to Divi's Laboratories Limited in 1994.
DIVISLAB Stock 12 Month Forecast
Average Price Target
₹7,717.50
▲(16.88% Upside)
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Lupin Limited
―
Suven Life Sciences Limited
―
Torrent Pharmaceuticals Ltd
―